论文部分内容阅读
目的分析和探讨临床上采用马来酸曲美布丁联合双歧杆菌三联活菌肠溶胶囊治疗肠易激综合征(IBS)患者的临床疗效。方法 110例IBS患者,随机分为对照组和治疗组,各55例。对照组患者采用马来酸曲美布丁进行治疗,治疗组患者采用马来酸曲美布丁联合双歧杆菌三联活菌肠溶胶囊进行治疗,比较两组患者的临床疗效及其不良反应情况。结果治疗组腹痛、腹泻的有效率明显高于对照组,差异有统计学意义(P<0.05),腹胀、便秘、排便异常及粪便性状异常有效率差异无统计学意义(P>0.05);治疗组总有效率96.36%高于对照组69.09%,差异有统计学意义(P<0.05)。两组治疗不良反应发生率差异无统计学意义(P>0.05)。结论消化内科临床上采用马来酸曲美布丁联合双歧杆菌三联活菌肠溶胶囊治疗IBS具有较好的临床效果,且无不良反应,能显著改善患者的生活质量,因此值得临床推广使用。
Objective To analyze and discuss the clinical efficacy of Trimebutine maleate and Bifidobacterium triple enteric-coated enteric-coated capsules in the treatment of patients with irritable bowel syndrome (IBS). Methods 110 cases of IBS patients were randomly divided into control group and treatment group, each 55 cases. The patients in the control group were treated with trimebutine maleate. The patients in the treatment group were treated with trimethoprim maleate and bifidobacterium triple enteric-coated enteric-coated capsules. The clinical efficacy and adverse reactions of the two groups were compared. Results The effective rate of abdominal pain and diarrhea in the treatment group was significantly higher than that in the control group (P <0.05), and there was no significant difference in the effective rates of abdominal distension, constipation, defecation abnormalities and stool abnormalities (P> 0.05) The total effective rate was 96.36% higher than 69.09% in the control group, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions The clinical use of trimethoprim maleate combined with live bifidobacterium enteric-coated enteric-coated capsules in digestive medicine clinically has a good clinical effect and no adverse reactions, which can significantly improve the quality of life of patients. Therefore, it is worthy of clinical promotion and use.